Forum Markets (FRMM) Competitors

$4.61 -0.17 (-3.56%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$4.65 +0.04 (+0.93%)

As of 05/8/2026 07:57 PM Eastern

FRMM vs. LXEO, CLYM, LRMR, PRTC, and BNTC

Should you be buying Forum Markets stock or one of its competitors? The main competitors of Forum Markets include Lexeo Therapeutics (LXEO), Climb Bio (CLYM), Larimar Therapeutics (LRMR), PureTech Health (PRTC), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry.

How does Forum Markets compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Lexeo Therapeutics' return on equity of -67.33% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-67.33%	-55.98%
Forum Markets	N/A	-254.74%	-132.82%

Lexeo Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Forum Markets has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Lexeo Therapeutics has higher earnings, but lower revenue than Forum Markets. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$2.19	N/A
Forum Markets	$6.55M	14.29	-$450.52M	-$39.19	N/A

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 15.1% of Forum Markets shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lexeo Therapeutics currently has a consensus price target of $18.88, indicating a potential upside of 223.76%. Forum Markets has a consensus price target of $5.00, indicating a potential upside of 8.46%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lexeo Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Forum Markets. MarketBeat recorded 1 mentions for Lexeo Therapeutics and 0 mentions for Forum Markets. Lexeo Therapeutics' average media sentiment score of 0.06 beat Forum Markets' score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Neutral
Forum Markets	Neutral

Summary

Lexeo Therapeutics beats Forum Markets on 12 of the 15 factors compared between the two stocks.

How does Forum Markets compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Climb Bio's return on equity of -30.27% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-30.27%	-29.20%
Forum Markets	N/A	-254.74%	-132.82%

Climb Bio has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Forum Markets has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Climb Bio has higher earnings, but lower revenue than Forum Markets. Climb Bio is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Forum Markets	$6.55M	14.29	-$450.52M	-$39.19	N/A

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Comparatively, 15.1% of Forum Markets shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Climb Bio currently has a consensus price target of $19.80, indicating a potential upside of 74.14%. Forum Markets has a consensus price target of $5.00, indicating a potential upside of 8.46%. Given Climb Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Climb Bio is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Climb Bio had 16 more articles in the media than Forum Markets. MarketBeat recorded 16 mentions for Climb Bio and 0 mentions for Forum Markets. Climb Bio's average media sentiment score of 0.72 beat Forum Markets' score of 0.00 indicating that Climb Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Climb Bio	Positive
Forum Markets	Neutral

Summary

Climb Bio beats Forum Markets on 11 of the 15 factors compared between the two stocks.

How does Forum Markets compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Larimar Therapeutics' return on equity of -137.70% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.70%	-101.43%
Forum Markets	N/A	-254.74%	-132.82%

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 15.1% of Forum Markets shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Larimar Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Forum Markets has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

Larimar Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 315.62%. Forum Markets has a consensus target price of $5.00, indicating a potential upside of 8.46%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Larimar Therapeutics has higher earnings, but lower revenue than Forum Markets. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.21	N/A
Forum Markets	$6.55M	14.29	-$450.52M	-$39.19	N/A

In the previous week, Larimar Therapeutics had 1 more articles in the media than Forum Markets. MarketBeat recorded 1 mentions for Larimar Therapeutics and 0 mentions for Forum Markets. Larimar Therapeutics' average media sentiment score of 0.88 beat Forum Markets' score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Larimar Therapeutics	Positive
Forum Markets	Neutral

Summary

Larimar Therapeutics beats Forum Markets on 11 of the 15 factors compared between the two stocks.

How does Forum Markets compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

PureTech Health's return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Forum Markets	N/A	-254.74%	-132.82%

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 15.1% of Forum Markets shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Forum Markets has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

Forum Markets has a consensus target price of $5.00, indicating a potential upside of 8.46%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts clearly believe Forum Markets is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PureTech Health has higher earnings, but lower revenue than Forum Markets.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	89.53	-$109.74M	N/A	N/A
Forum Markets	$6.55M	14.29	-$450.52M	-$39.19	N/A

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Forum Markets'average media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Forum Markets	Neutral

Summary

Forum Markets beats PureTech Health on 7 of the 11 factors compared between the two stocks.

How does Forum Markets compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Benitec Biopharma has higher earnings, but lower revenue than Forum Markets. Benitec Biopharma is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	5,272.73	-$37.92M	-$1.14	N/A
Forum Markets	$6.55M	14.29	-$450.52M	-$39.19	N/A

Benitec Biopharma presently has a consensus target price of $27.67, indicating a potential upside of 125.30%. Forum Markets has a consensus target price of $5.00, indicating a potential upside of 8.46%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Benitec Biopharma is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Benitec Biopharma had 1 more articles in the media than Forum Markets. MarketBeat recorded 1 mentions for Benitec Biopharma and 0 mentions for Forum Markets. Benitec Biopharma's average media sentiment score of 0.00 equaled Forum Markets'average media sentiment score.

Company	Overall Sentiment
Benitec Biopharma	Neutral
Forum Markets	Neutral

Benitec Biopharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Forum Markets has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 15.1% of Forum Markets shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Benitec Biopharma's return on equity of -38.92% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-38.92%	-37.68%
Forum Markets	N/A	-254.74%	-132.82%

Summary

Benitec Biopharma beats Forum Markets on 10 of the 14 factors compared between the two stocks.

Get Forum Markets News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRMM vs. The Competition

Export

Metric	Forum Markets	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$97.10M	$2.95B	$4.24B	$12.12B
Dividend Yield	N/A	15.22%	5.55%	5.20%
P/E Ratio	-0.12	13.21	23.65	25.39
Price / Sales	14.29	1,935.97	155.80	75.96
Price / Cash	N/A	26.55	49.21	53.47
Price / Book	0.37	3.51	39.96	6.81
Net Income	-$450.52M	-$42.77M	$114.66M	$333.04M
7 Day Performance	-21.20%	1.21%	0.85%	3.15%
1 Month Performance	125.98%	4.37%	4.46%	7.13%
1 Year Performance	N/A	21.29%	19.97%	41.22%

Forum Markets Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FRMM Forum Markets	0.7067 of 5 stars	$4.61 -3.6%	$5.00 +8.5%	N/A	$97.10M	$6.55M	N/A	7
LXEO Lexeo Therapeutics	1.9484 of 5 stars	$5.77 +1.2%	$18.88 +227.1%	N/A	$427.48M	N/A	N/A	58	Upcoming Earnings
CLYM Climb Bio	4.0566 of 5 stars	$8.91 +0.3%	$16.78 +88.3%	N/A	$425.62M	N/A	N/A	9	News Coverage Earnings Report Upcoming Earnings Analyst Forecast High Trading Volume
LRMR Larimar Therapeutics	4.2027 of 5 stars	$3.94 -3.0%	$16.50 +318.8%	N/A	$421.77M	N/A	N/A	30	Upcoming Earnings
PRTC PureTech Health	0.1581 of 5 stars	$18.14 +5.2%	N/A	N/A	$419.90M	$4.66M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FRMM) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forum Markets (FRMM) Competitors

FRMM vs. LXEO, CLYM, LRMR, PRTC, and BNTC

How does Forum Markets compare to Lexeo Therapeutics?

Summary

How does Forum Markets compare to Climb Bio?

Summary

How does Forum Markets compare to Larimar Therapeutics?

Summary

How does Forum Markets compare to PureTech Health?

Summary

How does Forum Markets compare to Benitec Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRMM vs. The Competition

Forum Markets Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forum Markets (FRMM) Competitors

FRMM vs. LXEO, CLYM, LRMR, PRTC, and BNTC

How does Forum Markets compare to Lexeo Therapeutics?

Is LXEO or FRMM more profitable?

Which has more risk & volatility, LXEO or FRMM?

Which has better valuation and earnings, LXEO or FRMM?

Do insiders & institutionals believe in LXEO or FRMM?

Do analysts prefer LXEO or FRMM?

Does the media refer more to LXEO or FRMM?

Summary

How does Forum Markets compare to Climb Bio?

Is CLYM or FRMM more profitable?

Which has more risk and volatility, CLYM or FRMM?

Which has stronger valuation & earnings, CLYM or FRMM?

Do institutionals & insiders believe in CLYM or FRMM?

Do analysts prefer CLYM or FRMM?

Does the media prefer CLYM or FRMM?

Summary

How does Forum Markets compare to Larimar Therapeutics?

Is LRMR or FRMM more profitable?

Do institutionals & insiders believe in LRMR or FRMM?

Which has more risk and volatility, LRMR or FRMM?

Do analysts rate LRMR or FRMM?

Which has higher earnings & valuation, LRMR or FRMM?

Does the media refer more to LRMR or FRMM?

Summary

How does Forum Markets compare to PureTech Health?

Is PRTC or FRMM more profitable?

Do institutionals & insiders believe in PRTC or FRMM?

Which has more risk and volatility, PRTC or FRMM?

Do analysts rate PRTC or FRMM?

Which has higher earnings & valuation, PRTC or FRMM?

Does the media refer more to PRTC or FRMM?

Summary

How does Forum Markets compare to Benitec Biopharma?

Which has higher earnings & valuation, BNTC or FRMM?

Do analysts rate BNTC or FRMM?

Does the media refer more to BNTC or FRMM?

Which has more risk and volatility, BNTC or FRMM?

Do institutionals & insiders believe in BNTC or FRMM?

Is BNTC or FRMM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRMM vs. The Competition

Forum Markets Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools